---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-24-000060"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:27:24.308866+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Emergent Q1 rev $300M, net income $9M; raises FY2024 adj EBITDA guidance to $125-175M

## Summary
- Q1 2024 total revenues $300.4M (up 83% YoY), net income $9.0M vs loss of $186.2M last year.
- Adjusted EBITDA $66.9M vs $(101.5)M; adjusted EPS $0.59 vs $(3.26).
- FY2024 guidance raised: total rev $1.0-1.1B, adj EBITDA $125-175M, adj net loss $(65)-(15)M.
- ASPR contract modification reduces minimum purchase from 9M to 3.5M doses annually for Option Years 5-9; max contract value revised to $1.4B.
- NARCAN sales up 18% to $118.5M; MCM segment gross margin improved to 60%.

## SEC filing metadata
- accession: 0001367644-24-000060
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000060/0001367644-24-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000060/ebs-20240429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-24-000060
- JSON: https://secwatch.observer/filing/0001367644-24-000060.json
- Plain text: https://secwatch.observer/filing/0001367644-24-000060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.